179 related articles for article (PubMed ID: 35468695)
21. Contemporary Biological Insights and Clinical Management of Craniopharyngioma.
Apps JR; Muller HL; Hankinson TC; Yock TI; Martinez-Barbera JP
Endocr Rev; 2023 May; 44(3):518-538. PubMed ID: 36574377
[TBL] [Abstract][Full Text] [Related]
22. Successful Use of BRAF/MEK Inhibitors as a Neoadjuvant Approach in the Definitive Treatment of Papillary Craniopharyngioma.
Khaddour K; Chicoine MR; Huang J; Dahiya S; Ansstas G
J Natl Compr Canc Netw; 2020 Dec; 18(12):1590-1595. PubMed ID: 33285519
[TBL] [Abstract][Full Text] [Related]
23. Biological Behaviour of Craniopharyngiomas.
Martinez-Barbera JP; Andoniadou CL
Neuroendocrinology; 2020; 110(9-10):797-804. PubMed ID: 32126562
[TBL] [Abstract][Full Text] [Related]
24. Adamantinomatous and papillary craniopharyngiomas are characterized by distinct epigenomic as well as mutational and transcriptomic profiles.
Hölsken A; Sill M; Merkle J; Schweizer L; Buchfelder M; Flitsch J; Fahlbusch R; Metzler M; Kool M; Pfister SM; von Deimling A; Capper D; Jones DT; Buslei R
Acta Neuropathol Commun; 2016 Feb; 4():20. PubMed ID: 26927026
[TBL] [Abstract][Full Text] [Related]
25. Do craniopharyngioma molecular signatures correlate with clinical characteristics?
Omay SB; Chen YN; Almeida JP; Ruiz-Treviño AS; Boockvar JA; Stieg PE; Greenfield JP; Souweidane MM; Kacker A; Pisapia DJ; Anand VK; Schwartz TH
J Neurosurg; 2018 May; 128(5):1473-1478. PubMed ID: 28707994
[TBL] [Abstract][Full Text] [Related]
26. Diagnosis and management of craniopharyngiomas in the era of genomics and targeted therapy.
Martinez-Gutierrez JC; D'Andrea MR; Cahill DP; Santagata S; Barker FG; Brastianos PK
Neurosurg Focus; 2016 Dec; 41(6):E2. PubMed ID: 27903124
[TBL] [Abstract][Full Text] [Related]
27. BRAF V600E mutations are characteristic for papillary craniopharyngioma and may coexist with CTNNB1-mutated adamantinomatous craniopharyngioma.
Larkin SJ; Preda V; Karavitaki N; Grossman A; Ansorge O
Acta Neuropathol; 2014; 127(6):927-9. PubMed ID: 24715106
[No Abstract] [Full Text] [Related]
28. Recurrent papillary craniopharyngioma with BRAFV600E mutation treated with neoadjuvant-targeted therapy.
Rostami E; Witt Nyström P; Libard S; Wikström J; Casar-Borota O; Gudjonsson O
Acta Neurochir (Wien); 2017 Nov; 159(11):2217-2221. PubMed ID: 28918496
[TBL] [Abstract][Full Text] [Related]
29. The molecular pathogenesis of craniopharyngiomas.
Campanini ML; Almeida JP; Martins CS; de Castro M
Arch Endocrinol Metab; 2023 Mar; 67(2):266-275. PubMed ID: 36748936
[TBL] [Abstract][Full Text] [Related]
30. Adamantinomatous craniopharyngioma: moving toward targeted therapies.
Hengartner AC; Prince E; Vijmasi T; Hankinson TC
Neurosurg Focus; 2020 Jan; 48(1):E7. PubMed ID: 31896087
[TBL] [Abstract][Full Text] [Related]
31. Genomic Alterations of Adamantinomatous and Papillary Craniopharyngioma.
Goschzik T; Gessi M; Dreschmann V; Gebhardt U; Wang L; Yamaguchi S; Wheeler DA; Lauriola L; Lau CC; Müller HL; Pietsch T
J Neuropathol Exp Neurol; 2017 Feb; 76(2):126-134. PubMed ID: 28069929
[TBL] [Abstract][Full Text] [Related]
32. First evidence of anti-VEGF efficacy in an adult case of adamantinomatous craniopharyngioma: Case report and illustrative review.
De Rosa A; Calvanese F; Ducray F; Vasiljevic A; Manet R; Raverot G; Jouanneau E
Ann Endocrinol (Paris); 2023 Dec; 84(6):727-733. PubMed ID: 37865272
[TBL] [Abstract][Full Text] [Related]
33. The Medical Therapy of Craniopharyngiomas: The Way Ahead.
Alexandraki KI; Kaltsas GA; Karavitaki N; Grossman AB
J Clin Endocrinol Metab; 2019 Dec; 104(12):5751-5764. PubMed ID: 31369091
[TBL] [Abstract][Full Text] [Related]
34. Molecular pathology of adamantinomatous craniopharyngioma: review and opportunities for practice.
Apps JR; Martinez-Barbera JP
Neurosurg Focus; 2016 Dec; 41(6):E4. PubMed ID: 27903120
[TBL] [Abstract][Full Text] [Related]
35. BRAF-V600E mutant papillary craniopharyngioma dramatically responds to combination BRAF and MEK inhibitors.
Roque A; Odia Y
CNS Oncol; 2017 Apr; 6(2):95-99. PubMed ID: 28425764
[TBL] [Abstract][Full Text] [Related]
36. Dramatic Response of BRAF V600E Mutant Papillary Craniopharyngioma to Targeted Therapy.
Brastianos PK; Shankar GM; Gill CM; Taylor-Weiner A; Nayyar N; Panka DJ; Sullivan RJ; Frederick DT; Abedalthagafi M; Jones PS; Dunn IF; Nahed BV; Romero JM; Louis DN; Getz G; Cahill DP; Santagata S; Curry WT; Barker FG
J Natl Cancer Inst; 2016 Feb; 108(2):. PubMed ID: 26498373
[TBL] [Abstract][Full Text] [Related]
37. Prediction of CTNNB1 Mutation Status in Pediatric Cystic Adamantinomatous Craniopharyngioma by Using Preoperative Magnetic Resonance Imaging Manifestation.
Zhu W; Tang T; Yuan S; Chang B; Li S; Chen M
Clin Neurol Neurosurg; 2021 Jan; 200():106347. PubMed ID: 33160718
[TBL] [Abstract][Full Text] [Related]
38. Prediction of BRAF mutation status of craniopharyngioma using magnetic resonance imaging features.
Yue Q; Yu Y; Shi Z; Wang Y; Zhu W; Du Z; Yao Z; Chen L; Mao Y
J Neurosurg; 2018 Jul; 129(1):27-34. PubMed ID: 28984520
[TBL] [Abstract][Full Text] [Related]
39. Targeted treatment of papillary craniopharyngiomas harboring BRAF V600E mutations.
Juratli TA; Jones PS; Wang N; Subramanian M; Aylwin SJB; Odia Y; Rostami E; Gudjonsson O; Shaw BL; Cahill DP; Galanis E; Barker FG; Santagata S; Brastianos PK
Cancer; 2019 Sep; 125(17):2910-2914. PubMed ID: 31314136
[TBL] [Abstract][Full Text] [Related]
40. A Clinical Rule for Preoperative Prediction of BRAF Mutation Status in Craniopharyngiomas.
Fujio S; Juratli TA; Arita K; Hirano H; Nagano Y; Takajo T; Yoshimoto K; Bihun IV; Kaplan AB; Nayyar N; Fink AL; Bertalan MS; Tummala SS; Curry WT; Jones PS; Martinez-Lage M; Cahill DP; Barker FG; Brastianos PK
Neurosurgery; 2019 Aug; 85(2):204-210. PubMed ID: 30481321
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
